関与物質
| 役割 | 名称 | HCID | 仕込み量 |
|---|
| 反応物 | 4-(3-Methoxyphenoxy)piperidine hydrochloride | HCID 17749795 | — |
| 反応物 | 6-Bromo-3-(trifluoromethyl)-(1,2,4)triazolo(4,3-a)pyridine | HCID 58118906 | — |
| 試薬 | Sodium t-butoxide | HCID 23676156 | — |
| 触媒 | Binap, (A+-)- | HCID 634876 | — |
| 触媒 | (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one; palladium | HCID 6505921 | — |
| 溶媒 | P-Xylene | HCID 7809 | — |
| 生成物 | 6-[4-(3-Methoxyphenoxy)piperidin-1-yl]-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine | HCID 59149683 | 30.51% |
反応手順
6-bromo-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine (100 mg, 0.38 mmol), 4-(3-methoxyphenoxy)piperidine hydrochloride (110 mg, 0.45 mmol), rac-2,2'-Bis(diphenylphosphino)-1,1'-binaphthyl (17.56 mg, 0.03 mmol) and Sodium tert-butoxide (0.161 mL, 1.32 mmol) were suspended in xylenes (5 mL), then de-gassed and purged with nitrogen. Bis(dibenzylideneacetone)palladium (10.81 mg, 0.02 mmol) was added, and the mixture was sealed into a microwave tube. The reaction was heated to 100 °C for 20 minutes in the microwave reactor and cooled to RT. The reaction mixture was diluted with EtOAc (25 mL), and washed with water (25 mL). The organic layer was purified by ion exchange chromatography, using an SCX column. The desired product was eluted from the column using 7M NH3/MeOH and pure fractions were evaporated to dryness to afford crude product. The crude product was purified by preparative HPLC (Waters XBridge Prep C18 OBD column, 5µ silica, 19 mm diameter, 100 mm length), using decreasingly polar mixtures of water (containing 1% NH3) and MeCN as eluents. Fractions containing the desired compound were evaporated to dryness to afford 6-(4-(3-methoxyphenoxy)piperidin-1-yl)-3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine (45.0 mg, 30.5 %) as a white solid.
情報源と証拠
| 出典データセット | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-65b9230d98a54611a7b2ba04f46f98c7 |
|---|
| 出典メモ | 750 AstraZeneca ELN dataset |
|---|